Ann: US Listing Update, page-56

Hi Glyco,

The ability to distinguish quality research varies from one individual to another. How potential investors interpret company news boils down to how experienced they are in moving around a Prospectus, Annual Report, 1/2 yearly, 4C and any releases from the company.

The delay in the CFDA Approval is frustrating and Dr G will be pulling his hair out with setback after setback from the Chinese government. Could this whole approval process be done differently, only Dr G could answer this conundrum.

IMHO GMV is still a company that has the potential to be a major global player in the Health Care Sector. Dr G has been building his workforce as he developes the company in different regions and he is primed to attack as soon as the CFDA Approval comes through.

GMV is not a train wreck but is a high risk buy at this stage. Good luck to all.

DYOR GLTAH

Cheers Rubes